Neoadjuvant imatinib for borderline resectable GIST.
Koontz MZ, Visser BM, Kunz PL. Neoadjuvant imatinib for borderline resectable GIST. Journal Of The National Comprehensive Cancer Network 2012, 10: 1477-82; quiz 1482. PMID: 23221786, DOI: 10.6004/jnccn.2012.0154.Peer-Reviewed Original ResearchMeSH KeywordsAdultBenzamidesFemaleGastrointestinal Stromal TumorsHumansImatinib MesylateNeoadjuvant TherapyPiperazinesProtein Kinase InhibitorsPyrimidinesRadiographyTreatment OutcomeConceptsGastrointestinal stromal tumorsNeoadjuvant imatinibNeoadjuvant tyrosine kinase-inhibitor therapyResectable gastrointestinal stromal tumorsTyrosine kinase inhibitor therapyBorderline resectable tumorsCommon bile ductSuperior mesenteric veinKinase inhibitor therapyOptimal imaging modalityViable treatment strategySpindle cell neoplasmResectable tumorsRed blood cellsUpper endoscopyBlack stoolInhibitor therapyBile ductMedical oncologyStromal tumorsEmergency departmentCase reportMesenteric veinCell neoplasmsTreatment strategies